Table 1. Patients’ Characteristics No.... | American Society of Hematology

Table 1.

Patients’ Characteristics

No. Morphology	Cytogenetics	% Blasts	CD34^*	% RhoD	Clinical Response^†
1. AML-M1	Normal	59	neg	<10	CCR
2. AML-M2	Normal	78	neg	<10	Rel within 6 mo
3. AML-M4	inv (3), −7	71	pos	33	PRes
4. AML-AUL	num ab	63	neg	27	PRes
5. AML-M4	Normal	57	neg	<10	PRes
6. AML-M2	t(7;11)	29	pos	<10	CCR
7. AML-M3	t(15;17)	64	neg	17	CCR
8. AML-M4	t(8;21)	62	pos	14	Rel after 2 yr
9. AML-M5b	Normal	64	neg	18	Rel within 1 yr
10. AML-M2	t(8;21)	87	pos	11	Rel after 2 yr
11. AML-M4	num ab	76	ND	24	PRes

No. Morphology	Cytogenetics	% Blasts	CD34^*	% RhoD	Clinical Response^†
1. AML-M1	Normal	59	neg	<10	CCR
2. AML-M2	Normal	78	neg	<10	Rel within 6 mo
3. AML-M4	inv (3), −7	71	pos	33	PRes
4. AML-AUL	num ab	63	neg	27	PRes
5. AML-M4	Normal	57	neg	<10	PRes
6. AML-M2	t(7;11)	29	pos	<10	CCR
7. AML-M3	t(15;17)	64	neg	17	CCR
8. AML-M4	t(8;21)	62	pos	14	Rel after 2 yr
9. AML-M5b	Normal	64	neg	18	Rel within 1 yr
10. AML-M2	t(8;21)	87	pos	11	Rel after 2 yr
11. AML-M4	num ab	76	ND	24	PRes

Abbreviations: CCR, continued complete remission; PRes, primary resistant; Rel, relapse; num ab, numerous aberrations; pos, positive; neg, negative; ND, not done.

Positive: >30% CD34 expressing cells.

†

Clinical response after anthracycline-containing regimen.

View Large

This Feature Is Available To Subscribers Only